A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biological effects, and impact on quality of life

Autor: Samuelsson, J., Hasselbalch, Hans Carl, Bruserud, O., Temerinac, S., Brandberg, Y., Merup, Y., Linder, O., Bjorkholm, M., Pahl, H.L., Birgegard, G.

Publikováno v: Samuelsson, J, Hasselbalch, H C, Bruserud, O, Temerinac, S, Brandberg, Y, Merup, Y, Linder, O, Bjorkholm, M, Pahl, H L & Birgegard, G 2006, ' A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biological effects, and impact on quality of life ', Syopa, vol. 106, no. 11, pp. 2397-2405 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::e581df406babf77ad20d0a83d8dc78cf
https://portal.findresearcher.sdu.dk/da/publications/dfbd63b0-cb1e-11db-a006-000ea68e967b